Clinical Trial Detail

NCT ID NCT03642626
Title MT2017-45: CAR-T Cell Therapy for Heme Malignancies
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Masonic Cancer Center, University of Minnesota
Indications

childhood B-cell acute lymphoblastic leukemia

B-cell adult acute lymphocytic leukemia

relapsed/refractory diffuse large B-cell lymphoma

Therapies

Cyclophosphamide + Fludarabine + Tisagenlecleucel

Cyclophosphamide + Fludarabine + KTE-C19

Age Groups: adult senior child

No variant requirements are available.